Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS1819-SD vs PERT in CF Patients with EPI
NCT03746483Phase 2Completed
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of adrulipase alfa in exocrine pancreatic insufficiency (EPI), sponsored by Entero Therapeutics, Inc.. Started Jan 2019; status: completed.
02
Drugs
adrulipase alfa
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT03746483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746483.